Abstract:Background: Endothelial cell (EC) dysfunction leading to microvascular alterations is a hallmark of technique failure in peritoneal dialysis (PD). However, the mechanisms underlying EC dysfunction in PD are poorly defined. Methods: We combined RNA sequencing with metabolite set analysis to characterize the metabolic profile of peritoneal ECs from a mouse model of PD. This was combined with EC-selective blockade of glycolysis by genetic or pharmacological inhibition of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) in vivo and in vitro. We also investigated the association between peritoneal EC glycolysis and microvascular alterations in human peritoneal samples from patients with end-stage kidney disease (ESKD). Results: In a mouse model of PD, peritoneal ECs had a hyperglycolytic metabolism that shunts intermediates into nucleotide synthesis. Hyperglycolytic mouse peritoneal ECs displayed a unique active phenotype with increased proliferation, permeability and inflammation. The active phenotype of mouse peritoneal ECs can be recapitulated in human umbilical venous ECs and primary human peritoneal ECs by vascular endothelial growth factor that was released from high glucose-treated mesothelial cells. Importantly, reduction of peritoneal EC glycolysis, via endothelial deficiency of the glycolytic activator PFKFB3, inhibited PD fluid-induced increases in peritoneal capillary density, vascular permeability and monocyte extravasation, thereby protecting the peritoneum from the development of structural and functional damages. Mechanistically, endothelial PFKFB3 deficiency induced the protective effects in part by inhibiting cell proliferation, VE-cadherin endocytosis and monocyte-adhesion molecule expression. Pharmacological PFKFB3 blockade induced a similar therapeutic benefit in this PD model. Human peritoneal tissue from patients with ESKD also demonstrated evidence of increased EC PFKFB3 expression associated with microvascular alterations and peritoneal dysfunction. Conclusions: These findings reveal a critical role of glycolysis in ECs in mediating the deterioration of peritoneal function and suggest that strategies targeting glycolysis in peritoneal ECs may be of therapeutic benefit for patients undergoing PD.

Inhibition of ADAM17 attenuates high glucose-induced angiogenesis and inflammation in endothelial cells partly through down-regulation of GRO-α/CXCR2 expression: implications in peritoneal dialysis

Inhibition of ADAM17 attenuates high glucose-induced angiogenesis and inflammation in endothelial cells partly through down-regulation of GRO-α/CXCR2 expression: implications in peritoneal dialysis

Adipocytes Exposed To High Glucose Potentiate Angiogenesis And Endothelial Dysfunction

Vascular endothelial growth factor-mediated peritoneal neoangiogenesis in peritoneal dialysis

Pharmacological Inhibition of Heparin-Binding EGF-like Growth Factor Promotes Peritoneal Angiogenesis in a Peritoneal Dialysis Rat Model.

Diabetic Patients Could Do As Well As Non-Diabetic Patients Without Inflammation on Peritoneal Dialysis

Angiogenic Role of Mesothelium-Derived Chemokine CXCL1 During Unfavorable Peritoneal Tissue Remodeling in Patients Receiving Peritoneal Dialysis as Renal Replacement Therapy

Accumulation of Tissue Advanced Glycation End Products Correlated with Glucose Exposure Dose and Associated with Cardiovascular Morbidity in Patients on Peritoneal Dialysis

Peritoneal morphologic changes in a peritoneal dialysis rat model correlate with angiopoietin/Tie-2

Hyperglycolysis in endothelial cells drives endothelial injury and microvascular alterations in peritoneal dialysis

RhoA/Rho-kinase Triggers Epithelial-Mesenchymal Transition in Mesothelial Cells and Contributes to the Pathogenesis of Dialysis-Related Peritoneal Fibrosis

Strategies for Preventing Peritoneal Fibrosis in Peritoneal Dialysis Patients: New Insights Based on Peritoneal Inflammation and Angiogenesis

Association of Peritoneal Angiogenesis with Angiopoietin-2 in Peritoneal Dialysis Rats

Protective Effect of COMP-angiopoietin-1 on Peritoneal Vascular Permeability and Peritoneal Transport Function in Uremic Peritoneal Dialysis Rats.

Genistein inhibits HIF-1α and attenuates high glucose-induced peritoneal mesothelial-mesenchymal transition and fibrosis via the mTOR/OGT pathway

Activation of AMPK-PGC-1α pathway ameliorates peritoneal dialysis related peritoneal fibrosis in mice by enhancing mitochondrial biogenesis

Up-regulation of Leptin in Adipocytes Exposed to High Glucose and Its Effect in Peritoneal Angiogenesis

Autophagy Promotes Fibrosis and Apoptosis in the Peritoneum During Long-Term Peritoneal Dialysis

Elevated Expression of HDAC6 in Clinical Peritoneal Dialysis Patients and Its Pathogenic Role on Peritoneal Angiogenesis

Effects of high glucose and methylglyoxal on expression of angiopoietin 2 in cultured human umbilical vascular endothelial cells

Inhibition of PI3K/AKT/mTOR Signalling Pathway Activates Autophagy and Suppresses Peritoneal Fibrosis in the Process of Peritoneal Dialysis